mab
isol
immun
infect
human
anim
use
librari
display
antibodi
fig
gene
encod
antibodi
heavi
light
chain
b
cell
immun
infect
human
anim
clone
fab
scfv
fragment
display
instanc
filament
phage
virusspecif
antibodi
isol
pan
librari
antigen
approach
use
isol
potent
neutral
antibodi
b
cell
rhesu
macaqu
immun
recombin
adenovirus
carri
synthet
gene
encod
hemagglutinin
ha
influenza
human
igm
memori
b
cell
recent
season
influenza
addit
pan
librari
construct
antibodi
repertoir
follow
infect
pan
nativ
antibodi
librari
yield
potent
neutral
antibodi
viral
infect
exampl
broadli
neutral
hiv
antibodi
isol
pan
nativ
antibodi
might
difficult
identifi
highli
neutral
antibodi
pan
nativ
phage
librari
lack
antibodi
somat
hypermut
process
disadvantag
may
overcom
vitro
affin
matur
step
pan
librari
construct
immun
infect
human
anim
donor
antibodi
somat
hypermut
took
place
given
viru
phage
display
effici
way
gener
viral
neutral
antibodi
immun
infect
nonimmun
human
anim
result
antibodi
necessarili
repres
natur
antibodi
repertoir
sinc
antibodi
fragment
gener
random
pare
igg
heavi
light
variabl
sinc
predefin
wellcharacter
antigen
requir
pan
librari
approach
suitabl
identifi
new
neutral
epitop
viral
abil
clone
antibodi
encod
gene
singl
b
cell
natur
infect
immun
individu
signific
advanc
isol
antivir
mab
three
differ
approach
develop
isol
mab
singlememori
b
cell
fig
one
approach
involv
isol
memori
b
cell
specif
viral
antigen
flow
cytometri
follow
direct
clone
antibodyencod
gene
without
cultur
b
cell
approach
appli
isol
neutral
antibodi
natur
infect
immun
human
donor
respiratori
syncyti
viru
rsv
antibodi
also
isol
method
antigenspecif
individu
memori
b
cell
rhesu
macaqu
immun
trimer
base
sinc
predefin
antigen
requir
identifi
memori
b
cell
isol
flow
cytometri
sort
abovement
approach
suitabl
identif
novel
neutral
target
identifi
novel
target
epitop
first
larg
number
memori
b
cell
cultur
cultur
supernat
screen
variou
antigen
approach
use
discoveri
broad
potent
neutral
antibodi
hiv
discoveri
new
vaccin
surfac
iggexpress
memori
b
cell
enrich
peripher
blood
mononuclear
cell
pbmc
infect
donor
neg
deplet
antibodi
igm
iga
igd
magnet
bead
individu
memori
b
cell
seed
microtiterpl
presenc
feeder
cell
condit
media
gener
mitogenstimul
human
cell
healthi
donor
supernat
collect
day
later
screen
antigenbind
reactiv
anoth
protocol
addit
cytokin
interleukin
il
irradi
feeder
cell
success
stimul
memori
b
cell
produc
high
concentr
igg
supernat
third
approach
b
cell
immort
epsteinbarr
viru
ebv
presenc
tolllik
receptor
approach
appli
isol
neutral
antibodi
rabi
sarscov
report
antigenspecif
plasma
cell
account
total
iggsecret
cell
peripher
blood
one
week
boost
method
clone
igg
human
antibodysecret
cell
develop
fig
approach
appli
isol
neutral
antibodi
natur
infect
immun
human
donor
protocol
clone
mab
nonhuman
primat
plasma
memori
b
cell
also
one
report
larg
panel
dengu
target
mab
clone
singleantibodysecret
b
cell
rhesu
macaqu
immun
experiment
singleantibodysecret
b
cell
identifi
isol
flow
cytometri
use
panel
phenotyp
interrog
larg
number
plasma
b
cell
method
develop
use
microwel
array
chip
method
enabl
analysi
live
cell
singlecel
basi
offer
rapid
effici
highthroughput
individu
cell
identif
antibodysecret
plasma
addit
direct
clone
antibodi
encod
gene
plasma
b
cell
singl
plasma
cell
also
cultur
monolay
immort
stromal
cell
stimul
cultur
cell
would
abl
produc
enough
antibodi
screen
assay
parallel
viral
bind
neutral
identifi
rare
antibodi
clone
singl
memori
plasma
b
cell
repres
genet
antibodi
repertoir
individu
given
time
respons
specif
viral
infect
howev
repertoir
necessarili
correspond
antibodi
present
circul
protocol
develop
identifi
antigenspecif
antibodi
sequenc
directli
circul
polyclon
antibodi
sera
immun
natur
infect
anim
human
fig
protocol
combin
power
proteom
nextgener
sequenc
ng
approach
involv
affin
purif
antibodi
antigen
specif
follow
analysi
proteolyt
digest
antibodi
fraction
liquid
spectrometri
peptid
spectral
match
antibodi
variabl
region
obtain
search
refer
databas
creat
ng
bcell
immunoglobulin
repertoir
immun
anim
human
final
heavi
light
chain
sequenc
pair
express
recombin
use
approach
mab
target
hbv
human
cytomegaloviru
hcmv
clone
human
approach
provid
altern
method
isol
potent
viral
neutral
antibodi
therapeut
purpos
promot
deeper
understand
humor
respons
clone
mab
individu
memori
plasma
b
cell
robust
effici
approach
isol
viralspecif
antibodi
approach
provid
snapshot
sampl
antibodi
genet
repertoir
individu
given
time
particular
viru
variou
deepsequenc
approach
provid
unbias
pictur
bcell
repertoir
base
either
heavi
chain
light
chain
inform
endogen
pair
heavi
light
chain
lost
bulk
lysi
bcell
phylogenet
match
heavi
light
chain
antibodi
deepsequenc
data
provid
approxim
natur
heavi
light
chain
highthroughput
sequenc
pair
heavi
light
chain
variabl
region
singlecel
level
proven
technic
challeng
method
allow
determin
pair
heavi
light
chain
variabl
region
repertoir
million
cell
high
precis
recent
briefli
flowfocus
use
encapsul
singl
cell
emuls
contain
magnet
bead
messeng
rna
mrna
captur
mrna
transcript
reversetranscrib
physic
link
partner
overlap
extens
pcr
interrog
highthroughput
pairedend
adapt
wide
research
commun
method
provid
power
inform
antibodi
respons
infect
vaccin
vaccin
efficaci
clone
potent
viral
neutral
combin
two
antihcmv
human
mab
bind
viral
gb
protein
bind
viral
gh
pentamer
also
known
isol
ebv
immort
b
cell
hcmvimmun
human
donor
result
clinic
trial
show
compon
mab
safe
well
toler
pharmacokinet
expect
human
phase
clinic
trial
stem
cell
transplant
patient
combin
two
mab
affinitymatur
version
bind
neutral
epitop
human
mab
isol
spleen
cell
hcmv
seroposit
individu
late
known
sever
name
includ
protovir
sdz
sdz
sevirumab
develop
sandoz
sever
clinic
trial
therapi
hcmv
develop
discontinu
fail
demonstr
improv
outcom
treatment
hcmv
retin
aid
patient
prevent
hcmv
infect
hematopoiet
stem
cell
addit
activ
develop
therapi
antibodi
subject
seri
mechanist
studi
includ
defin
mechan
hcmv
escap
neutral
compon
bind
pentamer
gh
isol
mous
hybridoma
subsequ
develop
genentech
treatment
prevent
hcmv
infect
utero
solid
organ
hematopoiet
stem
cell
transplant
recipi
phase
studi
show
safe
welltoler
favor
pharmacokinet
immunogen
profil
studi
support
develop
therapi
prevent
treatment
hcmv
infect
suscept
phase
trial
highrisk
kidney
transplant
recipi
well
toler
numer
reduc
incid
hcmv
infect
within
week
posttransplant
statist
signific
delay
time
hcmv
viremia
associ
case
hcmv
diseas
compar
mab
also
known
clone
singlehuman
plasmablast
cell
isol
influenza
vaccin
donor
bind
highli
conserv
epitop
stalk
influenza
ha
block
hamedi
membran
fusion
endosom
capabl
neutral
known
human
influenza
two
phase
clinic
trial
safe
well
toler
singl
intraven
dose
mg
mab
demonstr
linear
serum
pharmacokinet
consist
human
antibodi
lack
known
endogen
target
current
phase
clinic
trial
treatment
patient
hospit
sever
influenza
engin
human
target
stem
stalk
region
influenza
ha
demonstr
bind
group
group
influenza
prophylact
administr
result
complet
protect
mice
develop
acut
respiratori
distress
syndrom
lethal
influenza
viru
phase
clinic
trial
safe
well
toler
good
rel
exposur
serum
upper
respiratori
tract
result
support
use
either
singledos
therapeut
prophylact
influenza
current
phase
studi
design
assess
safeti
toler
antibodi
subject
uncompl
isol
combinatori
display
librari
construct
human
igm
memori
b
cell
season
influenza
vaccine
antibodi
neutral
viru
block
conform
rearrang
associ
membran
fusion
antibodi
protect
mice
given
lethal
recogn
highli
conserv
helic
region
membraneproxim
stem
antibodi
neutral
viru
block
conform
rearrang
associ
membran
current
phase
clinic
human
mab
broad
neutral
activ
group
virus
includ
caus
sever
human
infect
isol
b
cell
donor
vaccin
crystal
structur
fab
pandem
ha
reveal
highli
conserv
epitop
ha
stalk
distinct
epitop
recogn
v
h
group
test
phase
structur
comput
analys
indic
target
ha
residu
prone
antigen
drift
host
select
pressur
critic
escap
mutat
seen
certain
virus
recent
antibodi
isol
ab
igg
memori
b
cell
healthi
human
subject
antibodi
recogn
previous
unknown
conform
epitop
within
ectodomain
influenza
matrix
protein
antibodybind
region
highli
conserv
influenza
virus
region
present
nearli
strain
detect
date
includ
highli
pathogen
virus
infect
primarili
bird
swine
swineorigin
pandem
strain
soiv
addit
protect
mice
lethal
challeng
either
influenza
phase
clinic
studi
show
safe
evid
immun
exacerb
base
serum
cytokin
express
trial
also
show
antibodi
may
provid
immedi
immun
therapeut
benefit
influenza
infect
appar
emerg
resist
broadli
neutral
mab
isol
b
cell
hivinfect
direct
site
capabl
potent
neutral
divers
phase
studi
show
antibodi
safe
demonstr
expect
halflif
pharmacokinet
human
two
openlabel
trial
safeti
sideeffect
profil
pharmacokinet
properti
antivir
activ
test
person
hiv
infect
undergo
art
antiretrovir
therapi
interrupt
antibodi
slightli
delay
plasma
viral
rebound
trial
particip
compar
histor
control
maintain
viral
suppress
week
test
multipl
phase
human
antibodi
isol
singl
b
cell
patient
high
titer
broadli
neutral
antibodi
antibodi
bind
hiv
core
glycoprotein
stabil
conform
lack
variabl
v
loop
antibodi
block
infect
suppress
viremia
macaqu
infect
tropic
simianhuman
immunodefici
viru
shiv
emul
mani
pathogen
immunogen
properti
infect
rhesu
phase
trial
safe
effect
reduc
phase
trial
suppress
viral
rebound
human
treatment
interrupt
antibodi
exert
strong
select
pressur
emerg
latent
reservoir
analyt
treatment
interrupt
addit
suppress
viremia
individu
enhanc
host
humor
immun
antibodi
also
test
combin
function
similar
broadli
neutral
antibodi
treatment
antibodi
recogn
highli
conserv
membran
proxim
extern
region
ectodomain
stem
hiv
test
phase
trial
wellsuppress
haarttreat
individu
treat
acut
earli
addit
antibodi
directli
target
viral
antigen
prevent
treat
infect
antibodi
target
host
receptor
receptor
also
develop
hiv
infect
exampl
target
human
mab
pro
test
clinic
trial
antibodi
exhibit
potent
longliv
antivir
activ
gener
well
ibalizumab
imab
human
mab
bind
conform
epitop
block
entri
also
test
clinic
anoth
approach
bispecif
ab
combin
inhibitori
activ
ibalizumab
bnab
construct
passiv
immun
prevent
fda
approv
palivizumab
bind
f
glycoprotein
rsv
prophylaxi
children
suscept
sever
motavizumab
affin
matur
deriv
palivizumab
tenfold
potent
palivizumab
f
glycoprotein
phase
clinic
trial
motavizumab
recipi
rel
reduct
rsv
hospit
compar
palivizumab
recipi
motavizumab
superior
palivizumab
reduct
rsvspecif
outpati
lower
respiratori
tract
infect
malri
rel
reduct
halflif
extend
deriv
antibodi
known
motavizumabyt
motavizumab
aminoacid
substitut
yte
fcmodifi
antirsv
mab
also
test
phase
clearanc
motavizumabyt
significantli
lower
halflif
two
fourfold
longer
motavizumab
healthi
sustain
serum
concentr
motavizumabyt
fulli
function
shown
rsv
neutral
activ
persist
day
motavizumabyt
versu
day
postdos
despit
improv
motavizumab
motavizumabyt
palivizumab
clinic
benefit
consid
increment
approv
clinic
use
potent
palivizumab
vitro
deriv
mab
isol
b
cell
human
donor
target
perfus
conform
rsv
f
protein
engin
yte
substitut
within
fc
region
extend
halflif
phase
studi
mean
halflif
day
across
dose
group
safeti
profil
similar
current
phase
trial
healthi
preterm
infant
week
gestat
age
enter
first
rsv
anoth
human
igg
mab
target
rsvf
protein
current
phase
clinic
antibodi
singledomain
camelidderiv
antibodi
nanobodi
target
rsvf
protein
due
small
size
nanobodi
test
therapeut
inhal
phase
infant
age
month
hospit
rsv
outbreak
ebola
west
africa
affect
peopl
led
lesson
learn
handl
high
mortal
rate
epidem
contribut
call
take
innov
counter
measur
emerg
infecti
diseas
includ
use
mab
exampl
experiment
mab
cocktail
zmapp
given
special
approv
compassion
use
fastmov
epidem
zmapp
combin
three
mab
optim
two
previou
antibodi
cocktail
zmab
zmapp
show
protect
efficaci
rhesu
macaqu
challeng
howev
random
control
human
trial
zmapp
plu
current
standard
care
meet
statist
threshold
set
improv
efficaci
compar
current
standard
care
alon
effort
isol
potent
neutral
antibodi
ebola
ongo
exampl
potent
neutral
antibodi
target
ebola
viru
surfac
glycoprotein
ebov
gp
isol
sequenti
immun
rhesu
macaqu
antigenspecif
singl
bcell
similarli
potent
neutral
antibodi
target
ebola
ebov
gp
isol
peripher
b
cell
convalesc
donor
surviv
ebov
zair
highli
potent
neutral
mab
could
serv
promis
candid
prophylact
therapeut
intervent
ebola
outbreak
zika
associ
congenit
abnorm
also
increas
awar
urgent
need
take
measur
emerg
infecti
similar
combat
ebola
viral
infect
develop
vaccin
top
prioriti
protect
popul
zika
antibodybas
therapeut
also
propos
option
treatment
zika
exampl
two
antibodi
potent
zikvspecif
neutral
isol
singl
patient
provid
postexposur
protect
mice
structur
studi
reveal
bound
tertiari
epitop
envelop
protein
domain
ii
iii
indic
potenti
target
zikvspecif
rabi
occur
worldwid
almost
invari
fatal
clinic
symptom
rabi
mostli
prevent
postexposur
prophylaxi
pep
administ
clinic
symptom
develop
pep
consist
thorough
wound
cleans
follow
immedi
administr
rabi
immun
globulin
rig
togeth
full
cours
rabi
howev
due
lack
educ
avail
rig
vaccin
estim
global
canin
rabi
caus
death
mostli
asia
suppli
human
rig
hrig
equin
rig
erig
often
limit
desir
develop
potent
neutral
human
mab
replac
mixtur
two
human
mab
mab
bind
epitop
rabi
glycoprotein
isol
ebvtransform
memori
b
cell
human
subject
vaccin
inactiv
rabi
recogn
nonoverlap
epitop
isol
phagedisplay
antibodi
librari
construct
pbmc
rabi
viru
vaccin
human
evalu
multipl
phase
clinic
studi
safe
humab
also
known
gener
transgen
mice
carri
human
immunoglobulin
anoth
potent
rabi
viru
neutral
mab
test
multipl
clinic
trial
india
continu
effort
identifi
potent
broadli
neutral
mab
rabi
exampl
two
antibodi
potenc
broadspectrum
reactiv
identifi
immort
b
cell
vaccin
abl
neutral
strain
rabi
viru
vitro
furthermor
show
higher
potenc
breadth
compar
antibodi
clinic
develop
includ
hepat
b
establish
acut
chronic
infect
lead
seriou
liver
diseas
matern
fetal
transmiss
one
import
rout
keep
preval
high
region
hepat
b
endem
hepat
b
immunoglobulin
antibodi
prepar
one
form
countermeasur
mab
also
develop
supplement
suit
tool
avail
control
spread
hbv
associ
dengu
world
preval
mosquitoborn
diseas
estim
million
peopl
year
becom
sever
dengu
associ
infect
differ
strain
viru
character
vascular
permeabl
bleed
mucosa
intestin
tract
dengu
shock
syndrom
acut
renal
contrast
hcmv
sever
symptom
accompani
detect
activ
dengu
symptom
often
appear
peak
viremia
therefor
antibodi
appli
passiv
immunotherapi
would
use
onset
symptom
earli
enough
avoid
viremia
anoth
differ
hcmv
dengu
hcmv
develop
fetus
infant
peopl
compromis
immun
system
clearli
risk
develop
sever
contrast
clear
prognost
indic
suscept
sever
dengu
viru
diseas
prognost
indic
necessari
due
practic
limit
number
peopl
receiv
passiv
immunotherapi
dengu
antibodi
subneutr
concentr
may
enhanc
uptak
dengu
viru
way
dramat
aggrav
symptom
antibodydepend
enhanc
ade
therefor
develop
vaccin
focu
dengu
control
far
one
vaccin
approv
vaccin
cydtdv
dengvaxia
sanofi
pasteur
less
ideal
better
dengu
vaccin
urgent
mab
dengu
gener
interact
dengu
could
analyz
identifi
viru
best
target
epitop
key
first
step
vaccin
design
summari
epitop
associ
antibodi
present
sever
excel
epitop
target
antibodi
effect
neutral
dengu
viru
group
broad
classif
base
whether
epitop
present
singl
virion
epitop
monom
compos
featur
one
virion
quaternari
epitop
epitop
monom
group
accord
region
dengu
virion
bound
prm
protein
fle
amino
acid
bc
loop
e
protein
domain
ii
amino
acid
ediii
quaternari
epitop
also
subdivid
ede
epitop
edi
edii
ediii
e
protein
epitop
monom
edi
ediedii
hing
ediii
intact
virion
e
protein
herringbon
epitop
edi
ediedii
hing
ediii
although
dengu
antibodi
therapeut
reach
stage
clinic
trial
broadli
neutral
antibodi
potenti
develop
therapeut
dengu
dengu
target
antibodi
high
concentr
may
enhanc
infect
therefor
therapeut
antibodi
need
engin
abolish
interact
antibodi
macrophag
thu
prevent
exampl
mutat
fc
region
engin
reduc
affin
fc
region
result
mark
reduct
ade
activ
vitro
cell
anoth
studi
dengu
neutral
mab
target
distinct
epitop
four
denv
serotyp
engin
prevent
bind
introduc
lala
mutat
fc
region
lala
variant
enhanc
infect
neutral
denv
vitro
vivo
postexposur
therapi
mous
model
lethal
denv
one
mab
specif
rsv
approv
prophylaxi
use
viral
infect
sever
challeng
imped
progress
mani
antivir
mab
pipelin
one
key
challeng
rel
small
market
antibodi
treatment
viral
diseas
potenti
higher
cost
associ
product
recombin
antibodi
compar
small
molecul
antivir
anoth
key
challeng
competit
form
treatment
prevent
vaccin
often
still
best
approach
control
viral
infect
often
benefit
lifelong
immun
even
effect
mab
therapi
develop
widespread
applic
may
impract
due
high
cost
convent
product
compar
countermeasur
diseas
viral
infect
one
way
address
problem
high
cost
mab
therapi
reduc
cost
product
instanc
product
mab
scfv
fab
form
camelid
nanobodi
enabl
rel
inexpens
express
prokaryot
anoth
way
address
problem
high
cost
financ
partnership
tradit
donor
newer
fund
sourc
gate
foundat
exampl
develop
impact
bond
test
way
elimin
rabi
infect
dog
turn
reduc
demand
expens
treatment
third
key
challeng
complex
patholog
epidemiolog
immunolog
associ
infect
way
kinet
infect
inform
therapeut
strategi
instanc
explain
dengu
mab
clinic
trial
vaccin
prefer
method
control
influenza
dengu
influenza
symptom
often
appear
peak
viremia
antibodi
appli
passiv
immunotherapi
would
use
onset
symptom
earli
enough
avoid
viremia
one
potenti
solut
match
therapeut
antibodi
rapid
point
care
diagnost
test
diagnost
could
use
identifi
patient
infect
suscept
sever
diseas
would
benefit
passiv
immunotherapi
therapeut
antibodi
final
virus
complex
prevent
develop
singl
last
treatment
instanc
multipl
strain
rapid
evolut
obscur
mechan
infect
neutral
escap
discuss
fc
region
engin
shown
effect
increas
halflif
therapeut
antibodi
instanc
rsv
mab
motavizumab
yte
prevent
ade
reduc
fcr
bind
dengu
antibodi
interact
fc
domain
divers
receptor
provid
addit
opportun
engin
optim
therapeut
efficaci
antibodi
advantag
disadvantag
engin
approach
recent
review
bournazo
passiv
transfer
antibodi
prevent
treatment
viral
infect
easi
manag
high
cost
associ
antibodi
therapi
prohibit
prophylact
use
antibodi
intract
virus
hiv
influenza
viru
larg
popul
particularli
lowresourc
one
altern
passiv
administr
antibodi
therapi
involv
deliveri
transgen
encod
well
character
neutral
antibodi
vector
transgen
direct
express
antibodi
nonhematopoiet
cell
secret
mab
circul
demonstr
intramuscular
deliveri
electropor
synthet
dna
plasmid
engin
express
modifi
human
mab
multipl
denv
serotyp
confer
protect
denv
diseas
prevent
ade
diseas
work
need
clinic
applic
vector
deliveri
prophylact
therapeut
antibodi
viral
infect
promis
altern
current
practic
passiv
transfer
